Key Highlights

● MDxHealth reported Revenue up about 16% to roughly $27.2 million for the second quarter of 2026.

● The company described a rebound in revenue and maintained its guidance.

● MDxHealth markets genomic and other diagnostic tests used in urology, including prostate-cancer risk-assessment tests.

● The company's results depend on driving test adoption among urologists and securing reimbursement.

MDxHealth SA (NASDAQ:MDXH), a commercial-stage precision-diagnostics company focused on urologic cancers, reported double-digit revenue growth in the second quarter of 2026 and maintained its guidance.

MDxHealth offers a portfolio of specialized cancer tests and a growing revenue base, but as a company still working toward profitability, execution and reimbursement remain central.

Revenue Growth and Maintained Guidance

For the second quarter of 2026, MDxHealth reported revenue up about 16% to roughly $27.2 million, describing a rebound in revenue, and it maintained its guidance. The company markets genomic and other diagnostic tests used in urology, including tests that help determine the risk of prostate cancer and guide treatment decisions. The double-digit growth and maintained guidance suggest the company's genomic-testing Business continues to scale, though sustaining that pace will require continued adoption among urologists and favorable reimbursement dynamics.

Business and Financial Position

MDxHealth provides precision-diagnostic tests for urologic cancers, generating revenue from testing volumes across its portfolio, which includes tests for prostate-cancer risk assessment and treatment guidance. Its results depend on driving test adoption among urologists, securing and maintaining reimbursement from payers, and managing the costs of scaling a genomic-testing business. Investors should review the company's filings for test-volume trends, reimbursement coverage and progress toward profitability.

Market Context

Diagnostics stocks can be volatile around earnings, sensitive to test volumes, reimbursement news and profitability expectations, and a stock can move even after good revenue if the market focuses on margins or guidance nuances. MDxHealth's shares are likely to remain sensitive to continued test-volume growth and reimbursement developments.

Scaling a Genomic-Testing Business

Precision diagnostics for urologic cancers represents a growing but competitive market, where MDxHealth's tests must continue to demonstrate clinical value to urologists and secure consistent payer reimbursement to sustain growth. The 16% revenue increase is an encouraging sign of adoption, but converting that growth into sustainable profitability will require continued discipline on costs as the company scales its testing volumes.

What Investors Should Watch

The key signals are continued test-volume growth across MDxHealth's urologic-cancer portfolio, reimbursement coverage trends, and progress toward profitability. Investors will be monitoring competitive dynamics in precision diagnostics and the company's cost management as it scales. Execution and reimbursement risk are central considerations. Whether double-digit growth can continue depends on sustained adoption among urologists and stable payer coverage.